Globus Medical, Inc.
61.48-1.27 (-2.02%)
Oct 29, 4:00:02 PM EDT · NYSE · GMED · USD
Key Stats
Market Cap
8.30BP/E (TTM)
23.83Basic EPS (TTM)
2.58Dividend Yield
0%Recent Filings
8-K
Q2 sales soar 18.4% post-Nevro
Globus Medical reported Q2 2025 net sales of $745.3 million, up 18.4% year-over-year, fueled by the recent Nevro acquisition adding $94.6 million while base business grew 3.3%. US Spine surged 5.7%, but Enabling Technologies dipped slightly amid integration pushes. Non-GAAP diluted EPS hit a record $0.86, up 14.1%, yet GAAP figures swelled from a $110.6 million bargain purchase gain. The company closed Nevro and eyes synergies, reaffirming 2025 revenue guidance of $2.80-2.90 billion. Synergy execution poses integration risks.
10-Q
Q2 FY2025 results
Globus Medical's Q2 FY2025 results showed net sales climbing 18.4% y/y to $745.3M, fueled by the April Nevro acquisition adding $94.6M in revenue, while musculoskeletal solutions grew 19.7% y/y to $710.2M; U.S. sales surged 20.3% y/y, outpacing international's 11.0% y/y rise. Operating income jumped to $76.1M from $49.6M y/y, with gross margin expanding to 66.6% from 58.7% amid lower inventory step-up amortization, though SG&A swelled 26.8% y/y on integration costs. Diluted EPS hit $1.49, up from $0.23 y/y, reconciling to 136.5M weighted shares; the $110.6M bargain purchase gain from Nevro's deferred tax assets boosted net income to $202.8M. Cash dipped to $229.4M after $450M note repayment and $215.4M stock buybacks, yet operating cash flow strengthened to $255.2M YTD. Closed Nevro in April 2025 for $252.5M cash, recognizing $53.6M intangibles over 8-15 years. Patent disputes linger as a key risk.
8-K
CEO transition and strong Q2 sales
Globus Medical shook up its C-suite on July 18, 2025, with Daniel Scavilla resigning as CEO to chase another gig, paving the way for Keith Pfeil—former COO and CFO—to step in, while Kyle Kline took the CFO reins. This internal shuffle, free of any rifts, coincides with solid Q2 sales hitting $745.3 million, up 18.4% year-over-year, driven by US Spine's 7.4% day-adjusted growth and Enabling Tech gains. Leadership transition smooth. The company sticks to its $2.80–$2.90 billion full-year revenue guide, but integration risks from NuVasive and Nevro loom large.
8-K
Equity plan amendment approved
Globus Medical stockholders approved the amendment to its 2021 Equity Incentive Plan at the June 4, 2025 annual meeting, effective immediately, boosting the share pool to 11 million for employee and director incentives. The vote passed with 247 million for and 76 million against, while electing four directors and ratifying Deloitte as auditors. This strengthens talent retention amid growth. Annual say-on-pay votes will continue yearly.
8-K
Globus launches $500M buyback
Globus Medical announced a $500 million share repurchase program on May 15, 2025, signaling confidence amid recent stock volatility that has undervalued its strong growth and profitability track record. The board-authorized buyback, funded by cash reserves, will proceed via open market or private deals at management's discretion, aligning with long-term business investments. Yet risks like integration challenges with NuVasive and Nevro could sway outcomes.
IPO
Employees
Sector
Industry
BVS
Bioventus Inc.
6.77-0.17
CNMD
CONMED Corporation
46.71-0.61
ENOV
Enovis Corporation
31.99-0.87
FZMD
Fuse Medical, Inc.
0.08+0.00
GKOS
Glaukos Corporation
77.09-0.70
INSP
Inspire Medical Systems, Inc.
75.17-2.00
OFIX
Orthofix Medical Inc.
15.32-0.70
OSSFF
EMBLA MEDICAL
4.79+0.00
SIBN
SI-BONE, Inc.
15.26-0.53
ZBH
Zimmer Biomet Holdings, Inc.
99.71-1.43